Skip to content
10-K/A

Annual Report

SALIX PHARMACEUTICALS LTD

0001193125-15-073225

← back to feed
Filed
Mar 2, 2015 12:00 AM ET
Period of report
Amendment. Amends a previously filed report.
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2013 · Feb 24, 2014 63.33M sh
Long Term Debt FY 2013 · Dec 31, 2012 $1.05B
Current Liabilities FY 2013 · Dec 31, 2012 $260.92M
Current Assets FY 2013 · Dec 31, 2012 $1.19B
Total Assets FY 2013 · Dec 31, 2012 $1.87B
Eps Diluted FY 2013 · Dec 31, 2012 $0.28
Eps Diluted FY 2013 · Sep 30, 2012 $0.26
Eps Diluted restated FY 2013 · Jun 30, 2012 $0.15
Eps Diluted restated FY 2013 · Mar 31, 2012 $0.32
Eps Diluted FY 2013 · Dec 31, 2011 $1.44
Eps Basic FY 2013 · Dec 31, 2012 $0.30
Eps Basic FY 2013 · Sep 30, 2012 $0.28
Eps Basic restated FY 2013 · Jun 30, 2012 $0.17
Eps Basic restated FY 2013 · Mar 31, 2012 $0.35
Eps Basic FY 2013 · Dec 31, 2011 $1.49
Net Income FY 2013 · Dec 31, 2012 $17.62M
Net Income FY 2013 · Sep 30, 2012 $16.54M
Net Income restated FY 2013 · Jun 30, 2012 $9.95M
Net Income restated FY 2013 · Mar 31, 2012 $20.13M
Net Income FY 2013 · Dec 31, 2011 $87.4M
Cost Of Revenue FY 2013 · Dec 31, 2012 $30.68M
Cost Of Revenue FY 2013 · Sep 30, 2012 $26.47M
Cost Of Revenue restated FY 2013 · Jun 30, 2012 $34.19M
Cost Of Revenue restated FY 2013 · Mar 31, 2012 $33.26M
Cost Of Revenue FY 2013 · Dec 31, 2011 $95.37M
Revenue FY 2013 · Dec 31, 2012 $198.17M
Revenue FY 2013 · Sep 30, 2012 $185.13M
Revenue restated FY 2013 · Jun 30, 2012 $171.13M
Revenue restated FY 2013 · Mar 31, 2012 $181.01M
Revenue FY 2013 · Dec 31, 2011 $540.49M
Shares Diluted FY 2013 · Dec 31, 2011 65.48M sh
Capex FY 2013 · Dec 31, 2011 $26.14M
Operating Cash Flow FY 2013 · Dec 31, 2011 $119.15M
Sga Expense restated FY 2013 · Dec 31, 2011 $219.48M
Rd Expense restated FY 2013 · Dec 31, 2011 $71.86M
Operating Income FY 2013 · Dec 31, 2011 $115.87M
Cash And Equivalents FY 2013 · Dec 31, 2010 $518.03M
Stockholders Equity FY 2013 · Dec 31, 2010 $401.92M